Projects.
Insight.
Design.
Delivery.
Bringing access to life.
How we Operate
At Convalentis, we apply our Access Architecture™ — Plan · Build · Capture · Grow framework across diverse organizational needs.
Below are anonymized examples that illustrate how we help clients translate innovation into sustainable access and value.
Projext examples for…
Planning
Anticipating payer and policy expectations early
Pharma and
Biotech Leaders
Biotech
Innovators
Policy scenario planning for a high-stakes oncology launch across US and EU4+UK.
Follow the link to learn more
Biotech
Innovators
Healthcare
Organizations
Payer insight program for a rare disease asset to guide early access and reimbursement discussions in Europe.
Pharma and
Biotech Leaders
Investors
Policy environment review to identify system risks and opportunities in an anti-obesity investment target.
Building
Turning evidence into payer-recognized value
Pharma and
Biotech Leaders
Biotech
Innovators
Global payer value story for an orphan drug launch, planning for integration of post-approval real-world evidence (RWE) into access messaging.
Biotech
Innovators
Investors
Payer value assessment for an advanced-therapy medicinal product (ATMP) to support Series C financing and first EU payer interactions.
Follow the link to learn more
Investors
Evidence fit-gap review for late-stage pipeline assets across US, EU4+UK and Japan to inform valuation and exit strategy.
Capturing
Converting value into access and returns
Pharma and
Biotech Leaders
Healthcare
Organizations
Partnership & policy strategy to expand patient access for chronic care medications in Europe.
Follow the link to learn more
Biotech
Innovators
Investors
Early pricing & market access strategy for an orphan drug across US, EU4+UK and Japan to guide partnering and licensing negotiations with big pharma.
Investors
Pricing and access due diligence to quantify reimbursement risks and portfolio value levers.
Growing
Evolving organizations to stay ahead
Pharma and
Biotech Leaders
Redefinition of market access governance and capabilities for a regional hub.
Biotech
Innovators
Design of a lean European entry model for a US biotech, balancing in-house vs. outsourced access capacity.
Investors
Review of a portfolio company to identify capability gaps and development of an access readiness roadmap.
Follow the link to learn more
Healthcare
Organizations
Development of training modules for patient advocacy groups to impact access decision-making in selected Eastern European countries.